Perceptive Advisors LLC reduced its position in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 26.0% during the first quarter, Holdings Channel reports. The firm owned 622,873 shares of the biopharmaceutical company’s stock after selling 219,300 shares during the period. Perceptive Advisors LLC’s holdings in Abeona Therapeutics were worth $3,114,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Allianz Asset Management AG purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $236,000. A.R.T. Advisors LLC purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $117,000. GLG Partners LP purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $186,000. Tudor Investment Corp Et Al purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $162,000. Finally, Opaleye Management Inc. raised its stake in shares of Abeona Therapeutics by 300.0% in the fourth quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock worth $1,940,000 after buying an additional 300,000 shares during the period. 35.84% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) traded down 1.05% during mid-day trading on Friday, reaching $4.70. 191,091 shares of the company traded hands. The firm’s market capitalization is $189.20 million. The firm has a 50-day moving average price of $5.57 and a 200 day moving average price of $5.28. Abeona Therapeutics Inc. has a 52 week low of $2.31 and a 52 week high of $9.44.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.28 million. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. On average, analysts anticipate that Abeona Therapeutics Inc. will post ($0.58) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Shares Sold by Perceptive Advisors LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/06/16/abeona-therapeutics-inc-abeo-shares-sold-by-perceptive-advisors-llc.html.

Several equities research analysts have recently commented on ABEO shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Abeona Therapeutics in a research report on Friday, February 17th. Cantor Fitzgerald reissued a “positive” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, February 17th. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Friday, February 17th. FBR & Co reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Friday, February 17th. Finally, Zacks Investment Research cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $15.18.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc. (NASDAQ:ABEO).

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.